Anthera Pharmaceuticals to Participate in the Citi 12th Annual Biotech Conference

HAYWARD, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy, today announced its participation in the Citi 12th Annual Biotech Conference.  Anthera will host meetings at the Citi Biotech Conference in Boston on Thursday, September 7th.

Additional information on Anthera can be found at www.anthera.com

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

www.twitter.com/antherapharmahttps://www.facebook.com/antherapharma/ https://www.linkedin.com/company/anthera-pharmaceuticals

Contact Information

CONTACT: Investor Relations of Anthera Pharmaceuticals, Inc.
[email protected]

For Media Inquiries:
Srikant Ramaswami
rbb Communications
[email protected]
718-710-1350

Source: Anthera Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Enovis to acquire eCential Robotics for up to €211M
• Solidion Technology adds three independent directors to its board
• XTEND and JFB to merge, list on NYSE as XTEND AI Robotics